Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
Status:
Completed
Trial end date:
2009-03-25
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in
acute treatment of multiple migraine attacks with or without aura. Primary hypotheses of this
study are that telcagepant is superior to placebo, as measured by the proportion of
participants who have pain freedom, pain relief, pain freedom consistency, pain relief
consistency, and absence of photophobia, phonophobia, and nausea at 2 hours post-dose.